Abstract
Patient-derived organoids (PDOs) are powerful tools for modeling cancer, yet they often lack the complex tumor microenvironment (TME) that drives disease progression. This study presents a colorectal cancer (CRC) model that integrates epithelial tumor cells with patient-matched stromal fibroblasts. By characterizing cancer-associated fibroblasts (CAFs) and normal fibroblasts (NFs), the researchers demonstrate that these stromal cells support organoid growth without exogenous niche factors. Crucially, the co-culture model restores the cellular heterogeneity and morphological characteristics of the original tumor, providing a more physiologically relevant platform for studying CRC mechanisms and therapy response.
Introduction: The Missing Stroma
The shift from 2D cell lines to 3D patient-derived organoids (PDOs) has significantly advanced oncology by preserving the molecular characteristics of individual tumors. However, most standard PDOs are "naked," consisting almost entirely of epithelial tumor cells. In a clinical setting, colorectal tumors exist within a dense neighborhood of immune cells, blood vessels, and fibroblasts.
Fibroblasts, particularly Cancer-Associated Fibroblasts (CAFs), are known to drive tumor growth, promote metastasis, and shield cancer cells from chemotherapy. Because standard PDOs lack these neighbors, they often fail to accurately predict how a patient will respond to treatments like oxaliplatin. This research addresses this gap by creating a "patient-matched" model that includes both the cancer cells and the supporting stromal cells from the same individual.
Methodology and Multi-Omic Validation
The research team developed a 3D co-culture system using cells from patients with moderately differentiated colorectal tumors. Their approach involved several key innovations:
- Patient-Matched Isolation: Epithelial tumor cells and fibroblasts (both CAFs from the tumor and Normal Fibroblasts from adjacent healthy tissue) were isolated from the same surgical specimens.
- Niche-Independent Growth: Standard organoids require an expensive "cocktail" of growth factors (such as Wnt3a and EGF). The researchers tested a "minimal medium" (1% serum) to determine if fibroblasts could naturally provide these essential signals.
- Bioinformatic Deconvolution: To prove the co-culture was more realistic, the team used computational techniques to "deconvolve" bulk RNA-seq data. By comparing their results to published single-cell RNA-seq (scRNA-seq) datasets from CRC tissues (including the SMC and Li et al. datasets), they estimated the exact proportions of cell subtypes, such as stem cells versus mature colonocytes.
Key Insights: Fibroblasts as Signal Factories
A striking finding was that fibroblasts alone could support organoid growth and survival in minimal media. This confirms that the stroma provides the necessary "niche factors" that researchers typically add manually. Proteomic analysis further revealed that CAFs maintain a "constantly activated" state in vitro, exhibiting higher motility and increased secretion of pro-metastatic factors compared to normal fibroblasts.
Restoring Cellular Heterogeneity
In standard expansion media, organoids tend to become uniform and stem-cell-like. Adding fibroblasts restored the natural cellular diversity of the tumor. Histological staining (H&E, PAS, and markers like CK20) showed that co-cultures closely mirrored the architecture and mucus production of the original patient biopsy. The presence of fibroblasts induced the development of specialized cells like goblet cells and enterocytes, which are often missing in mono-cultures.
Mutual Molecular Instruction
The crosstalk between tumor cells and fibroblasts is a two-way street. RNA-seq revealed 1,742 significantly deregulated genes in organoids when grown with fibroblasts, primarily in pathways related to collagen biosynthesis and the innate immune system. Simultaneously, tumor cells "instructed" fibroblasts to adopt pro-inflammatory and matrix-remodeling phenotypes, upregulating specific markers such as WNT2, WNT5a, and VCAM1.
Conclusion and Future Directions
By incorporating the stromal component, this patient-matched model bridges the gap between simplified organoids and complex human tumors. While the model currently lacks immune and endothelial components, it provides a blueprint for the next generation of physiological cancer models. Future work will focus on longer-term cultures and clinical validation to determine if this co-culture model can better predict a patient's actual response to chemotherapy than standard methods, moving us closer to truly personalized oncology.
Summary updated